DACH Healthcare Innovation Summit 2023

Hosted by Bamberg Health

Event Hybrid in Munich

Venue: Holiday Inn Munich - Westpark, an IHG Hotel
Address: Albert-Roßhaupter-Straße 45, Munich, Germany
Tipocs: Health Digital Transformation, Artificial Intelligence & Big Data, Hospital Infrastructure & Medical Equipment, Therapeutic innovation & Pharma

The digital revolution impacts on our healthcare systems and it is on us to understand how to use new data and technical solutions for a positive integration in medical, clinical and administrative workflows. Changes will accelerate as discoveries and knowledge advance in a feedback loop creating a constant debate between highest healthcare authorities.

Our Healthcare Innovation Summit offers an open minded surrounding to connect and discuss the conversation of new ideas and necessary changes with those, responsible for the digital transformation of healthcare, experts in Artificial Intelligence and Big Data, those responsible for hospital infrastructures and medical equipment, and representatives of biotechnological and pharmaceutical therapeutic innovation of the DACH region.
Areas to be covered:

Health Digital Transformation
Artificial Intelligence and Big Data
Therapeutic Innovation & Pharma
Hospital Infrastructure & Medical Equipment

Speakers


  • Dr Karl BroichFederal German Institute for Drugs and Medical Devices (BfArM)President
    Dr Karl Broich Federal German Institute for Drugs and Medical Devices (BfArM) President
  • Dr Christoph HuberJohannes-Gutenberg University Medical Center Mainz, BioNTechProfessor emeritus of Hematology-Oncology at Johannes-Gutenberg University Medical Center Mainz, Co-founder of BioNTech
    Current professional activities: • Prof. emeritus internal medicine with focus on hematology, oncology & translational immunology, Johannes-Gutenberg University Mainz • Founding president and board member of the Association of Cancer Immunotherapy (CIMT) and president of the European Network for Cancer Immunotherapy (ENCI) • Board member of the high-tech cluster “Individualized Immune Intervention” (CI3) • Co-founder, scientific advisor, and supervisory board member of the companies Immugenix, Ganymed GmbH, BioNTech SE and TRON gGmbH LIFE PORTRAIT: I come from an Austrian family of scholars. I was born in Vienna in 1944 as the fourth child of Paul Huber who chairman of the Department of Surgery at the Leopold-Franzens-University in Innsbruck. After attending secondary school at the Schottengymnasium in Vienna and the Academic Gymnasium in Innsbruck, I studied medicine at Leopold Franzens University in Innsbruck. Prof. Herbert Braunsteiner trained me to be a specialist in internal medicine at the Innsbruck University Hospital, where in 1976 I qualified as a professor for internal medicine. Research and training residencies in immunology and stem cell transplantation took me to the Karolinska Institute for Tumor Biology in Stockholm, the Department of Immunology at the Wallenberg Institute in Uppsala, and the Fred Hutchinson Cancer Research Center in Seattle where I worked under the later Nobel Prize laureate Prof. Don Thomas. In 1984, I was appointed Professor of Clinical Immunobiology and Stem Cell Transplantation and head of the department of the same name at the Leopold Franzens University in Innsbruck. From 1990 to 2009, I headed the 3rd Medical Clinic at the University Medical Center of the Johannes Gutenberg University Mainz with a focus on hematology, oncology, translational immunology and stem cell transplantation. As a clinician, I set up a science-driven, innovative stem cell transplant and immunotherapy program at the University Medical Centre in Innsbruck and then developed the Mainz University Medical Center into a leading international center for immune-oncology and stem cell transplantation. I also founded a successful hematology-oncology school which filled numerous relevant professorships in Germany, Austria, the Netherlands, and Sweden. As a research manager, expert and consultant, I founded academic research structures such as the Collaborative Research Center 432 “Tumor Defense" and the clinical research group 410 "Lymphocyte Defense" both funded by the German Research Foundation. I was also founder of the first tumor vaccination center in Europe, which was built and financed by the German Cancer Aid, and founder and long-term president of the leading research network in Europe “Association of Cancer Immunotherapy (CIMT)” www.cimt.eu; president of the newly founded European umbrella organization “European Network for Cancer Immunotherapy (ENCI)” www.enci.network, of the translational oncology institute TRON gGmbH http://www.tron-mainz.de and the high-tech cluster "Individualized Immune Intervention - CI3" www.ci3.de of the German federal government. I was editor of international journals, textbooks and handbooks; a reviewer or function holder of national and international research funding organizations (Senate Commission of the German Research Foundation; advisor to the "Experimental Cancer Medicine Center" program of Cancer Research UK, the ISREC program of Swiss Science Foundation, the research commission of the German Cancer Aid; chairman of the “Commission somatic gene therapy” of the German Medical Association; curator of the Austrian Fund for the Promotion of Scientific Research and scientific advisor to all major German research institutions in the life sciences (German Cancer Research Center Heidelberg, Max Delbrück Center Berlin, Helmholtz Center for Environment and Health Munich) and the Paul Ehrlich Institute in Langen, the German regulatory authority for vaccines and biomedical drugs. For the past 22 years, I have also been an entrepreneur involved in research transfer and the founding and consulting of biotech companies. In 2001, I founded Ganymed Pharmaceuticals AG with my partners Prof. Ugur Sahin and Prof. Özlem Türeci as well as BioNTech SE http://www.biontech.de in 2008 and the non-profit translational research institute TRON gGmbH http://www.tron-mainz.de in 2009. Ganymed successfully developed clinically validated monoclonal antibodies against proprietary tumor antigens, thereby doubling the life expectancy of patients with tumors of the upper gastrointestinal tract. Ganymed was sold in 2016 to the big pharma group Astellas, which is currently testing the antibody in several approval studies. BioNTech is now a NASDAQ listed biotech company with > 4000 employees. It is one of the global leaders in the development of highly innovative mRNA-based immunotherapeutic agents against cancer and infectious diseases. BioNTech and its partner companies Pfizer and Fosun have developed the world's first approved COVID19 vaccine. These and other highly innovative drugs are currently being further developed in large-scale cooperation deals with leading pharmaceutical companies (Genentech/Roche, Sanofi, Eli Lilly, Pfizer, Bayer, Genmab, Fosun, Regeneron, and others). In addition to my entrepreneurial work, I have been an internationally active mentor for academic spin-off companies, a member of the scientific advisory boards of pharmaceutical and biotechnology companies as well as of strategic investors in Germany, UK, France, Austria, Norway, and the USA. I am an honorary member of the Austrian Academy of Sciences, recipient of honorary doctorates from the University of Innsbruck and the Johannes-Gutenberg-University in Mainz and of other awards (Federal Crosses of Merit of the FRG and the Republic of Austria, Order of Merit of the State of Rhineland-Palatinate, and the State of Tyrol ) and prizes (Future Price of the Federal Republic of Germany, Carl-Friederich-von-Weizsäcker Price of the German National Academy of Sciences, among others).
    Dr Christoph Huber Johannes-Gutenberg University Medical Center Mainz, BioNTech Professor emeritus of Hematology-Oncology at Johannes-Gutenberg University Medical Center Mainz, Co-founder of BioNTech
  • Dr Jochen WernerUniversity Hospital of EssenMedical Director and CEO
    Dr Jochen Werner University Hospital of Essen Medical Director and CEO
  • Dr Konrad Karcz Ludwig-Maximilians University of MunichHead of Minimally Invasive and Robotic Surgery at the Department of Gen., Abd. and Transplant Surgery
    Dr Konrad Karcz Ludwig-Maximilians University of Munich Head of Minimally Invasive and Robotic Surgery at the Department of Gen., Abd. and Transplant Surgery
  • Dr Lukas LürkenZentrum für Radiologisch-Interventionelle Onkologie (RIO), University Hospital of RegensburgDirector
    Dr Lukas Lürken Zentrum für Radiologisch-Interventionelle Onkologie (RIO), University Hospital of Regensburg Director
  • Rudolf DückUniversity Hospital Schleswig-Holstein (UKSH)CIO
    Rudolf Dück University Hospital Schleswig-Holstein (UKSH) CIO
  • Ralph Müller-EiseltBertelsmann StiftungDirector of Digitisation and the Common Good
    Ralph Müller-Eiselt Bertelsmann Stiftung Director of Digitisation and the Common Good

Sessions Download agenda


  • 1 Welcome Remarks -
    0 speakers
    The expected duration is 15 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 2 1st Panel: New challenges for Innovation in Healthcare -
    1 speakers
    • Dr Jochen WernerUniversity Hospital of EssenMedical Director and CEO
      Dr Jochen Werner University Hospital of Essen Medical Director and CEO
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 3 2nd Panel: Fostering a new ecosystem of interoperability -
    0 speakers
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 4 Coffee Break & Networking -
    0 speakers
    The expected duration is 30 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 5 Presentation -
    0 speakers
    The expected duration is 15 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 6 3rd Panel: A forward-looking view of Big Data and AI in the new medicine -
    2 speakers
    • Rudolf DückUniversity Hospital Schleswig-Holstein (UKSH)CIO
      Rudolf Dück University Hospital Schleswig-Holstein (UKSH) CIO
    • Ralph Müller-EiseltBertelsmann StiftungDirector of Digitisation and the Common Good
      Ralph Müller-Eiselt Bertelsmann Stiftung Director of Digitisation and the Common Good
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 7 4th Panel: Progress in Therapeutic Innovation -
    1 speakers
    • Dr Lukas LürkenZentrum für Radiologisch-Interventionelle Onkologie (RIO), University Hospital of RegensburgDirector
      Dr Lukas Lürken Zentrum für Radiologisch-Interventionelle Onkologie (RIO), University Hospital of Regensburg Director
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 8 5th Panel: Pharmaceutical innovation and access challenges -
    2 speakers
    • Dr Karl BroichFederal German Institute for Drugs and Medical Devices (BfArM)President
      Dr Karl Broich Federal German Institute for Drugs and Medical Devices (BfArM) President
    • Dr Christoph HuberJohannes-Gutenberg University Medical Center Mainz, BioNTechProfessor emeritus of Hematology-Oncology at Johannes-Gutenberg University Medical Center Mainz, Co-founder of BioNTech
      Current professional activities: • Prof. emeritus internal medicine with focus on hematology, oncology & translational immunology, Johannes-Gutenberg University Mainz • Founding president and board member of the Association of Cancer Immunotherapy (CIMT) and president of the European Network for Cancer Immunotherapy (ENCI) • Board member of the high-tech cluster “Individualized Immune Intervention” (CI3) • Co-founder, scientific advisor, and supervisory board member of the companies Immugenix, Ganymed GmbH, BioNTech SE and TRON gGmbH LIFE PORTRAIT: I come from an Austrian family of scholars. I was born in Vienna in 1944 as the fourth child of Paul Huber who chairman of the Department of Surgery at the Leopold-Franzens-University in Innsbruck. After attending secondary school at the Schottengymnasium in Vienna and the Academic Gymnasium in Innsbruck, I studied medicine at Leopold Franzens University in Innsbruck. Prof. Herbert Braunsteiner trained me to be a specialist in internal medicine at the Innsbruck University Hospital, where in 1976 I qualified as a professor for internal medicine. Research and training residencies in immunology and stem cell transplantation took me to the Karolinska Institute for Tumor Biology in Stockholm, the Department of Immunology at the Wallenberg Institute in Uppsala, and the Fred Hutchinson Cancer Research Center in Seattle where I worked under the later Nobel Prize laureate Prof. Don Thomas. In 1984, I was appointed Professor of Clinical Immunobiology and Stem Cell Transplantation and head of the department of the same name at the Leopold Franzens University in Innsbruck. From 1990 to 2009, I headed the 3rd Medical Clinic at the University Medical Center of the Johannes Gutenberg University Mainz with a focus on hematology, oncology, translational immunology and stem cell transplantation. As a clinician, I set up a science-driven, innovative stem cell transplant and immunotherapy program at the University Medical Centre in Innsbruck and then developed the Mainz University Medical Center into a leading international center for immune-oncology and stem cell transplantation. I also founded a successful hematology-oncology school which filled numerous relevant professorships in Germany, Austria, the Netherlands, and Sweden. As a research manager, expert and consultant, I founded academic research structures such as the Collaborative Research Center 432 “Tumor Defense" and the clinical research group 410 "Lymphocyte Defense" both funded by the German Research Foundation. I was also founder of the first tumor vaccination center in Europe, which was built and financed by the German Cancer Aid, and founder and long-term president of the leading research network in Europe “Association of Cancer Immunotherapy (CIMT)” www.cimt.eu; president of the newly founded European umbrella organization “European Network for Cancer Immunotherapy (ENCI)” www.enci.network, of the translational oncology institute TRON gGmbH http://www.tron-mainz.de and the high-tech cluster "Individualized Immune Intervention - CI3" www.ci3.de of the German federal government. I was editor of international journals, textbooks and handbooks; a reviewer or function holder of national and international research funding organizations (Senate Commission of the German Research Foundation; advisor to the "Experimental Cancer Medicine Center" program of Cancer Research UK, the ISREC program of Swiss Science Foundation, the research commission of the German Cancer Aid; chairman of the “Commission somatic gene therapy” of the German Medical Association; curator of the Austrian Fund for the Promotion of Scientific Research and scientific advisor to all major German research institutions in the life sciences (German Cancer Research Center Heidelberg, Max Delbrück Center Berlin, Helmholtz Center for Environment and Health Munich) and the Paul Ehrlich Institute in Langen, the German regulatory authority for vaccines and biomedical drugs. For the past 22 years, I have also been an entrepreneur involved in research transfer and the founding and consulting of biotech companies. In 2001, I founded Ganymed Pharmaceuticals AG with my partners Prof. Ugur Sahin and Prof. Özlem Türeci as well as BioNTech SE http://www.biontech.de in 2008 and the non-profit translational research institute TRON gGmbH http://www.tron-mainz.de in 2009. Ganymed successfully developed clinically validated monoclonal antibodies against proprietary tumor antigens, thereby doubling the life expectancy of patients with tumors of the upper gastrointestinal tract. Ganymed was sold in 2016 to the big pharma group Astellas, which is currently testing the antibody in several approval studies. BioNTech is now a NASDAQ listed biotech company with > 4000 employees. It is one of the global leaders in the development of highly innovative mRNA-based immunotherapeutic agents against cancer and infectious diseases. BioNTech and its partner companies Pfizer and Fosun have developed the world's first approved COVID19 vaccine. These and other highly innovative drugs are currently being further developed in large-scale cooperation deals with leading pharmaceutical companies (Genentech/Roche, Sanofi, Eli Lilly, Pfizer, Bayer, Genmab, Fosun, Regeneron, and others). In addition to my entrepreneurial work, I have been an internationally active mentor for academic spin-off companies, a member of the scientific advisory boards of pharmaceutical and biotechnology companies as well as of strategic investors in Germany, UK, France, Austria, Norway, and the USA. I am an honorary member of the Austrian Academy of Sciences, recipient of honorary doctorates from the University of Innsbruck and the Johannes-Gutenberg-University in Mainz and of other awards (Federal Crosses of Merit of the FRG and the Republic of Austria, Order of Merit of the State of Rhineland-Palatinate, and the State of Tyrol ) and prizes (Future Price of the Federal Republic of Germany, Carl-Friederich-von-Weizsäcker Price of the German National Academy of Sciences, among others).
      Dr Christoph Huber Johannes-Gutenberg University Medical Center Mainz, BioNTech Professor emeritus of Hematology-Oncology at Johannes-Gutenberg University Medical Center Mainz, Co-founder of BioNTech
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 9 Lunch & Networking -
    0 speakers
    The expected duration is 1 hour and 5 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 10 Presentation Smart Hospital -
    0 speakers
    The expected duration is 3 months and 27 days
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 11 6th Panel: The Intelligent Hospital: Innovative Equipment and Technologies -
    1 speakers
    • Dr Konrad Karcz Ludwig-Maximilians University of MunichHead of Minimally Invasive and Robotic Surgery at the Department of Gen., Abd. and Transplant Surgery
      Dr Konrad Karcz Ludwig-Maximilians University of Munich Head of Minimally Invasive and Robotic Surgery at the Department of Gen., Abd. and Transplant Surgery
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 12 7th Panel: Infrastructure: The Key to Improving Healthcare -
    0 speakers
    The expected duration is 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR
  • 13 Closing Remarks -
    0 speakers
    The expected duration is 4 months and 50 minutes
    The language of this session is æsessions_language_de;
    ADD TO CALENDAR

Target Audience


  • CIO's
    35%
  • CEO’s
    25%
  • Hospital Pharmacy Directors
    20%
  • Equipment and Infrastructure Directors
    20%

Event attendees


In order to view the attendees of this event and access the networking space, it is necessary to create an account and register for the event.
CREATE AN ACCOUNT

Medical Events

Learn, share and meet with the highest professionals in the healthcare industry.

Bamberg Health is a platform designed for health professionals focused on providing new knowledge and coverage on the healthcare, pharmaceutical, biotech, food, and health technology industries through virtual and in-person events

SIGN UP